Patricia Lillo, Pedro Zitko, Gladys Godoy-Reyes, Gabriela Asenjo, David Sáez, Gonzalo Cea, Pamela Navarrete, Daniel Valenzuela, Ricardo Hughes, Mark Heverin, Giancarlo Logroscino, Orla Hardiman
{"title":"智利肌萎缩性脊髓侧索硬化症的发病率。","authors":"Patricia Lillo, Pedro Zitko, Gladys Godoy-Reyes, Gabriela Asenjo, David Sáez, Gonzalo Cea, Pamela Navarrete, Daniel Valenzuela, Ricardo Hughes, Mark Heverin, Giancarlo Logroscino, Orla Hardiman","doi":"10.1080/21678421.2024.2329706","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to estimate amyotrophic lateral sclerosis (ALS) incidence and survival rates in the Metropolitan region of Chile.</p><p><strong>Methods: </strong>We conducted a cohort study of ALS cases in the Metropolitan Region from 2016 to 2019. A total of 219 ALS patients were recruited from Corporación ELA-Chile registry, in collaboration with neurologists from Sociedad de Neurología, Psiquiatría y Neurocirugía de Chile. We calculated incidence rates by sex and age and determined median survival from onset and diagnosis. Survival analysis used the Kaplan-Meier statistic, estimating hazard ratios for age, sex, time from symptom onset and from diagnosis using a Weibull regression model. All analyses were done using R 4.1.0.</p><p><strong>Results: </strong>Overall, ALS diagnosis incidence was 0.97 cases per 100,000 inhabitants, peaking in the 70-79 age group and declining thereafter. The male-to-female ratio was 1.23. The median time to death from diagnosis was 2.3 years (95% confidence interval [CI]: 1.9-2.5), and from the first symptom, it was 3.1 years (95% CI: 2.8-3.5).</p><p><strong>Conclusions: </strong>This is the first population-based study reporting ALS incidence and survival rates in Chile's Metropolitan region. Incidence resembled other Latin American studies. Median survival from diagnosis and from the first symptom were in line with previous findings. Our results corroborated lower ALS rates in Latin America, consistent with prior research.</p>","PeriodicalId":72184,"journal":{"name":"Amyotrophic lateral sclerosis & frontotemporal degeneration","volume":" ","pages":"528-532"},"PeriodicalIF":0.0000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Incidence of amyotrophic lateral sclerosis in Chile.\",\"authors\":\"Patricia Lillo, Pedro Zitko, Gladys Godoy-Reyes, Gabriela Asenjo, David Sáez, Gonzalo Cea, Pamela Navarrete, Daniel Valenzuela, Ricardo Hughes, Mark Heverin, Giancarlo Logroscino, Orla Hardiman\",\"doi\":\"10.1080/21678421.2024.2329706\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>This study aimed to estimate amyotrophic lateral sclerosis (ALS) incidence and survival rates in the Metropolitan region of Chile.</p><p><strong>Methods: </strong>We conducted a cohort study of ALS cases in the Metropolitan Region from 2016 to 2019. A total of 219 ALS patients were recruited from Corporación ELA-Chile registry, in collaboration with neurologists from Sociedad de Neurología, Psiquiatría y Neurocirugía de Chile. We calculated incidence rates by sex and age and determined median survival from onset and diagnosis. Survival analysis used the Kaplan-Meier statistic, estimating hazard ratios for age, sex, time from symptom onset and from diagnosis using a Weibull regression model. All analyses were done using R 4.1.0.</p><p><strong>Results: </strong>Overall, ALS diagnosis incidence was 0.97 cases per 100,000 inhabitants, peaking in the 70-79 age group and declining thereafter. The male-to-female ratio was 1.23. The median time to death from diagnosis was 2.3 years (95% confidence interval [CI]: 1.9-2.5), and from the first symptom, it was 3.1 years (95% CI: 2.8-3.5).</p><p><strong>Conclusions: </strong>This is the first population-based study reporting ALS incidence and survival rates in Chile's Metropolitan region. Incidence resembled other Latin American studies. Median survival from diagnosis and from the first symptom were in line with previous findings. Our results corroborated lower ALS rates in Latin America, consistent with prior research.</p>\",\"PeriodicalId\":72184,\"journal\":{\"name\":\"Amyotrophic lateral sclerosis & frontotemporal degeneration\",\"volume\":\" \",\"pages\":\"528-532\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Amyotrophic lateral sclerosis & frontotemporal degeneration\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1080/21678421.2024.2329706\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/3/20 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Amyotrophic lateral sclerosis & frontotemporal degeneration","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/21678421.2024.2329706","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/3/20 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
研究目的本研究旨在估算智利首都大区肌萎缩性脊髓侧索硬化症(ALS)的发病率和存活率:我们对 2016 年至 2019 年首都大区的 ALS 病例进行了一项队列研究。我们与智利神经病学、精神病学和神经病学协会的神经病学家合作,从Corporación ELA-Chile登记处共招募了219名ALS患者。我们按性别和年龄计算了发病率,并确定了发病和确诊后的中位生存期。生存期分析采用 Kaplan-Meier 统计法,通过 Weibull 回归模型估算出年龄、性别、发病时间和确诊时间的危险比。所有分析均使用 R 4.1.0 进行:总体而言,每 10 万居民中 ALS 诊断发病率为 0.97 例,在 70-79 岁年龄组达到峰值,之后逐渐下降。男女比例为 1.23。从确诊到死亡的中位时间为 2.3 年(95% 置信区间 [CI]:1.9-2.5),从首次出现症状到死亡的中位时间为 3.1 年(95% 置信区间 [CI]:2.8-3.5):这是第一项基于人口的研究,报告了智利大都会地区 ALS 的发病率和存活率。发病率与拉丁美洲的其他研究相似。确诊后和首次出现症状后的中位生存率与之前的研究结果一致。我们的研究结果证实,拉丁美洲的 ALS 发病率较低,这与之前的研究结果一致。
Incidence of amyotrophic lateral sclerosis in Chile.
Objective: This study aimed to estimate amyotrophic lateral sclerosis (ALS) incidence and survival rates in the Metropolitan region of Chile.
Methods: We conducted a cohort study of ALS cases in the Metropolitan Region from 2016 to 2019. A total of 219 ALS patients were recruited from Corporación ELA-Chile registry, in collaboration with neurologists from Sociedad de Neurología, Psiquiatría y Neurocirugía de Chile. We calculated incidence rates by sex and age and determined median survival from onset and diagnosis. Survival analysis used the Kaplan-Meier statistic, estimating hazard ratios for age, sex, time from symptom onset and from diagnosis using a Weibull regression model. All analyses were done using R 4.1.0.
Results: Overall, ALS diagnosis incidence was 0.97 cases per 100,000 inhabitants, peaking in the 70-79 age group and declining thereafter. The male-to-female ratio was 1.23. The median time to death from diagnosis was 2.3 years (95% confidence interval [CI]: 1.9-2.5), and from the first symptom, it was 3.1 years (95% CI: 2.8-3.5).
Conclusions: This is the first population-based study reporting ALS incidence and survival rates in Chile's Metropolitan region. Incidence resembled other Latin American studies. Median survival from diagnosis and from the first symptom were in line with previous findings. Our results corroborated lower ALS rates in Latin America, consistent with prior research.